Company: WHWK
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001628280-25-020311
Chunk: 22

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 22
---
 is responsible for evaluating and overseeing the management of a particular risk or risks, the chairman of the relevant committee reports on the discussion to the full Board during the committee reports portion of the next board meeting. This enables the Board and its committees to coordinate the risk oversight role, particularly with respect to risk interrelationships.

Board Meetings and Attendance

The Board held 13 meetings during 2024, and each of the incumbent directors of the board attended at least 75% of the aggregate of all meetings of the Board and all m eetings of committees of our Board upon which they served (during the periods that they served) during 2024. The Board regularly holds executive sessions of the independent directors. Executive sessions do not include employee directors or directors who do not qualify as independent under SEC rules. Although we do not have a formal policy regarding attendance by members of our Board at the annual meeting of stockholders, members of our board are encouraged to attend. Three of our directors attended the 2024 Annual Meeting of Stockholders.

<div align='center'>12</div>

#### Board Committees
We have established the following standing board committees: Audit Committee, Compensation Committee and a Nominating and Corporate Governance Committee. Each committee operates pursuant to a charter adopted by our Board. The composition and functioning of all committees comply with all applicable requirements of the Sarbanes-Oxley Act of 2002, SEC rules and regulations, and Nasdaq.

The following table sets forth which directors currently serve on each committee of the Board.

| Audit                 |     | Compensation           |     | Nominating and Corporate Governance |
| Emma Reeve (Chair)    |     | Richard Maroun (Chair) |     | Anupam Dalal, M.D. (Chair)          |
| Caley Castelein, M.D. |     | Anupam Dalal, M.D.     |     | Behzad Aghazadeh, Ph.D.             |
| Richard Maroun        |     | Caley Castelein, M.D.  |     | Karin Hehenberger, M.D., Ph.D.*     |

| * |     | Based on the recommendation of the nominating and corporate governance committee, our Board has decided not to nominate Dr. Hehenberger for re-election to our Board at the Annual Meeting after the expiration of her term at the Annual Meeting. As such, as of the Annual Meeting, Dr. Hehenberger will no longer serve as a member of the nominating and corporate